SEC Form 4 · accession 0000905718-15-000535
CANCER GENETICS, INC · CGIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raju S.K. Chaganti
Director
Period of report
Jun 9, 2015
Accepted (ET)
Jun 11, 2015 · 6:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001349929
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1,F2 | Jun 9, 2015 | S | 7,737 | $12.0129 | D | 176,240 | D | |
| Common Stock, par value $0.0001 per shareF1,F3 | Jun 10, 2015 | S | 22,817 | $12.0261 | D | 153,423 | D | |
| Common Stock, par value $0.0001 per shareF1,F4 | Jun 11, 2015 | S | 15,900 | $12.0452 | D | 137,523 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan.
- F2The price reported in Column 4 is a weighted average price. These shares were exercised in multiple transactions at prices ranging from $12.00 to $12.05, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares exercised at each separate price within the ranges set forth in footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were exercised in multiple transactions at prices ranging from $12.00 to $12.15, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares exercised at each separate price within the ranges set forth in footnote (3) to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were exercised in multiple transactions at prices ranging from $12.00 to $12.16, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares exercised at each separate price within the ranges set forth in footnote (4) to this Form 4.